阿吗碱在异喹胍/鹰爪豆碱代谢快者和代谢慢者体内的代谢情况
Metabolism of almitrine in extensive and poor metabolisers of debrisoquine/sparteine.
作者信息
Herchuelz A, Gangji D, Derenne F, Jeanniot J P, Douchamps J
机构信息
Unité de Pharmacologie Clinique, Hôpital Vésale, Montigny-le-Tilleul France.
出版信息
Br J Clin Pharmacol. 1991 Jan;31(1):73-6. doi: 10.1111/j.1365-2125.1991.tb03859.x.
Abstract
- Almitrine bismesylate displays wide inter-subject variation in peak plasma concentrations and can induce peripheral polyneuropathy. 2. The phenotyped volunteer panel approach was used to examine whether almitrine oxidation displayed a genetic polymorphism of the debrisoquine/sparteine type. 3. There was no difference between poor and extensive metabolisers of debrisoquine with respect to the pharmacokinetics and metabolism of almitrine.
摘要
- 二甲磺酸烯丙米特的血浆峰浓度在个体间存在很大差异，并且可诱发周围性多神经病。2. 采用表型志愿者组方法来研究烯丙米特氧化是否表现出异喹胍/鹰爪豆碱型的遗传多态性。3. 就烯丙米特的药代动力学和代谢而言，异喹胍慢代谢者和快代谢者之间没有差异。
相似文献
1
Metabolism of almitrine in extensive and poor metabolisers of debrisoquine/sparteine.阿吗碱在异喹胍/鹰爪豆碱代谢快者和代谢慢者体内的代谢情况
Br J Clin Pharmacol. 1991 Jan;31(1):73-6. doi: 10.1111/j.1365-2125.1991.tb03859.x.
2
Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal.司巴丁/异喹胍氧化的基因多态性：重新评估
Pharmacol Toxicol. 1990 Oct;67(4):273-83. doi: 10.1111/j.1600-0773.1990.tb00830.x.
3
The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.运用分析双峰分布的新方法对人司巴丁和异喹胍代谢的遗传控制。
J Med Genet. 1983 Oct;20(5):321-9. doi: 10.1136/jmg.20.5.321.
4
Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers?司巴丁/异喹胍的代谢不良者是否比代谢正常者对疼痛的耐受性更低？
Pain. 1993 Jun;53(3):335-339. doi: 10.1016/0304-3959(93)90229-I.
5
The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis.
Eur J Clin Pharmacol. 1997;51(5):389-93. doi: 10.1007/s002280050219.
6
The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.美西律的代谢与去甲异喹胍/鹰爪豆碱型药物氧化多态性的关系。
Br J Clin Pharmacol. 1991 Oct;32(4):459-66. doi: 10.1111/j.1365-2125.1991.tb03931.x.
7
Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.日本人群中三种测试探针（美托洛尔、异喹胍和司巴丁）代谢率之间与遗传决定的氧化多态性的相关性。
Br J Clin Pharmacol. 1990 Jan;29(1):111-5. doi: 10.1111/j.1365-2125.1990.tb03609.x.
8
Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers.
Eur J Clin Pharmacol. 1992;43(4):399-403. doi: 10.1007/BF02220616.
9
Metabolic oxidation of methaqualone in extensive and poor metabolisers of debrisoquine.安非他明在异喹胍代谢快和代谢慢的人群中的代谢氧化作用。
Eur J Clin Pharmacol. 1982;23(2):147-50. doi: 10.1007/BF00545969.
10
Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.丙咪嗪及其代谢产物的稳态浓度与司巴丁/异喹胍多态性的关系。
Eur J Clin Pharmacol. 1986;30(6):679-84. doi: 10.1007/BF00608215.
本文引用的文献
1
Pharmacokinetics of almitrine bismesylate: studies in patients.
Eur J Respir Dis Suppl. 1983;126:363-75.
2
The biodisposition of almitrine bismesylate in man: a review.
Eur J Respir Dis Suppl. 1983;126:337-48.
3
Effects and handling of almitrine bismesylate in healthy subjects.
Eur J Respir Dis Suppl. 1983;126:275-89.
4
[Clinical pharmacokinetics of almitrine dimesylate].
Presse Med. 1984 Oct 4;13(34):2071-7.
5
Almitrine bismesylate: current status.
Bull Eur Physiopathol Respir. 1987 Aug;23 Suppl 11:153s-163s.
6
[Neuropathies and almitrine. 14 cases].
Rev Neurol (Paris). 1987;143(6-7):510-9.
7
Peripheral neuropathy in patients treated with almitrine dimesylate.
Lancet. 1985 Jun 1;1(8440):1247-50. doi: 10.1016/s0140-6736(85)92315-3.
8
Extensive oxidative metabolism of dextromethorphan in patients with almitrine neuropathy.患有烯丙哌三嗪神经病变患者中右美沙芬的广泛氧化代谢。
Br J Clin Pharmacol. 1989 Mar;27(3):387-90. doi: 10.1111/j.1365-2125.1989.tb05382.x.
9
Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.人司巴丁N-氧化缺陷：一种新的药物遗传学缺陷。
Eur J Clin Pharmacol. 1979 Sep;16(3):183-7. doi: 10.1007/BF00562059.
10
Polymorphic hydroxylation of Debrisoquine in man.人对异喹胍的多态性羟基化作用。
Lancet. 1977 Sep 17;2(8038):584-6. doi: 10.1016/s0140-6736(77)91430-1.
Zotero 插件